Andrew X. Zhu
朱秀轩
MD, PhD
Director, Liver Cancer Research Program肝癌研究项目主任
👥Biography 个人简介
Andrew Zhu is a world-leading HCC researcher who led pivotal trials of ramucirumab and cabozantinib in advanced liver cancer, establishing two new standard-of-care second-line agents. His molecular biology work has elucidated HCC angiogenic and signaling pathways.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Ramucirumab in HCC
Led the REACH-2 trial identifying AFP-high patients as a biomarker-selected population benefiting from ramucirumab, the first biomarker-driven approval in HCC.
Cabozantinib in HCC
Contributed to the CELESTIAL trial establishing cabozantinib as a second-line standard of care after sorafenib progression in advanced HCC.
HCC Angiogenic Pathways
Conducted translational research delineating VEGF, MET, and FGF signaling roles in HCC progression, informing multi-kinase inhibitor development.
Representative Works 代表性著作
Ramucirumab after sorafenib in HCC with elevated AFP (REACH-2)
Lancet Oncology (2019)
First biomarker-selected RCT in HCC demonstrating survival benefit, enabling AFP-guided treatment stratification.
Cabozantinib in HCC after sorafenib (CELESTIAL)
New England Journal of Medicine (2018)
Phase III trial establishing cabozantinib as second-line standard, expanding options after first-line failure.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 朱秀轩 的研究动态
Follow Andrew X. Zhu's research updates
留下邮箱，当我们发布与 Andrew X. Zhu（Massachusetts General Hospital, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment